Neurologic complications of atrial fibrillation: Pharmacologic and interventional approaches to stroke prevention

Area of Science:

• Cardiology
• Vascular Medicine
• Thrombosis Research

Background:

• Atrial fibrillation (AF) is a prevalent cardiac arrhythmia associated with a significant risk of stroke.
• The CHA2DS2-VASc score is a standard tool for stratifying stroke risk in AF patients.
• Left atrial appendage (LAA) thrombi are the primary source of emboli causing stroke in AF.

Purpose of the Study:

• To review current strategies for stroke risk reduction in atrial fibrillation.
• To compare the efficacy and safety of direct oral anticoagulants (DOACs) with warfarin.
• To evaluate interventional left atrial appendage closure (LAAC) devices against warfarin.

Main Methods:

• Review of randomized controlled trials (RCTs) comparing DOACs to warfarin for stroke prevention in AF.
• Analysis of RCTs evaluating LAAC devices against warfarin.
• Assessment of stroke and bleeding risk data from relevant clinical trials.

Main Results:

• DOACs demonstrate favorable stroke and bleeding risk profiles compared to warfarin in RCTs.
• The Watchman device is the only LAAC device to show non-inferiority to warfarin in RCTs for stroke risk reduction.
• Both DOACs and LAAC devices represent viable alternatives to warfarin for stroke prevention in AF.

Conclusions:

• Direct oral anticoagulants offer an effective and safer alternative to warfarin for stroke prevention in atrial fibrillation.
• The Watchman device provides an effective alternative to warfarin for patients with atrial fibrillation seeking to reduce stroke risk via LAA closure.
• Risk stratification using CHA2DS2-VASc score guides the selection of appropriate stroke prevention strategies in atrial fibrillation.